HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata

NCT ID: NCT07049328

Last Updated: 2025-10-17

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-08-16
• Study Completion Date: 2026-12-15

Brief Summary

This is a Phase 1, open-label, multi-center, competitive enrollment, and dose-escalation study of HCW9302 in subjects with Alopecia Areata (AA)

Detailed Description

The study involves dose escalation to determine the toxicity profile of HCW9302 and to designate a dose level for the Phase 2 expansion phase (RP2D).

Up to five HCW9302 dose levels will be evaluated. A step-down dose level (level -1) will be provided in the event that unacceptable toxicity is encountered at the planned initial dose level. In the first stage of the study, HCW9302 will be administered subcutaneously as a single dose. Depending on the results of the single ascending dose stage, a multidose study of HCW9302 administered subcutaneously every 28 days for 4 consecutive treatments will be considered.

Conditions

Alopecia Areata(AA)

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Study of HCW9302, an IL-2 fusion protein, for alopecia areata

Single dose subcutaneous injection of HCW9302.

Group Type: EXPERIMENTAL

HCW9302, an IL-2 fusion protein

Intervention Type: DRUG

Injection

Interventions

HCW9302, an IL-2 fusion protein

Injection

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Adult women who are 18 to 70 years of age, or adult males who are 18 to 60 years of age at the time of informed consent.

2. Clinical diagnosis of Alopecia Areata (AA) (including ophiasis, totalis or universalis forms) at Screening.

3. Negative serum pregnancy test within 14 days of treatment start if female and of childbearing potential (non-childbearing is defined as greater than one year postmenopausal or surgically sterilized).

4. Female subjects of childbearing potential must adhere to using a highly effective medically accepted method of birth control (defined as those with failure less than 1%; see Appendix 2) prior to screening and agree to continue its use for at least 28 days after the last dose of HCW9302 or be surgically sterilized (e.g., hysterectomy or tubal ligation) and males must agree to use a barrier method of birth control and agree to continue its use for at least 28 days after the last dose of HCW9302.

5. Laboratory tests performed within 28 days of treatment start:

1. Absolute neutrophil count (AGC/ANC) ≥ 1,500/μL (≥1.5 × 109/L)

2. Platelets ≥ 100,000/μL (≥ 100 × 109/L)

3. Hemoglobin ≥ 10 g/dL (>100g/L)

4. Calculated glomerular filtration rate (GFR)* >40 mL/min OR serum creatinine ≤ 1.5 × ULN

5. Total bilirubin ≤ 2.0 × ULN or ≤ 3.0 × ULN for subjects with Gilbert's syndrome

6. AST, ALT, ALP ≤ 2.0 × ULN

6. Able and willing to comply with requested study visits and procedures.

7. Able and willing to provide written informed consent and HIPAA authorization

Exclusion Criteria

1. Men and women (of reproductive potential) unwilling to use birth control and women who are pregnant or breastfeeding

2. Patient has primarily "diffuse" type AA (characterized by diffuse hair shedding)

3. Presence of another form of alopecia

4. Prior use of any of the following treatments: a. Aldesleukin b. Investigational IL-2 analog

5. Concurrent use of oral or topical treatments targeting hair growth or hair restoration (including but not limited to finasteride, dutasteride, topical minoxidil or oral minoxidil) if discontinuation or dosage change is planned during the study period.

6. Prior use of phototherapy and any systemic immunosuppressant (systemic steroids, cyclosporin, methotrexate or any other immunosuppressive therapy) or immunomodulating biologic therapy (including but not limited to dupilumab, tralokinumab, lebrikizumab, nemolizumab, rocatinlimab, or daxdilimab, whether marketed or investigational) within 3 months prior to Screening.

7. Prior use of any B-cell depleting agents, whether marketed or investigational, including but not limited to rituximab, ocrelizumab, ofatumumab, or belimumab, within 6 months prior to Screening.

8. Known hypersensitivity or history of allergic reactions attributed to compounds of similar chemical or biologic composition to the agents used in the study.

9. History of diabetes mellitus, regardless of whether it is controlled or not.

10. History of myocardial infarction, congestive heart failure, uncontrolled arrhythmias, cardiac revascularization, stroke, uncontrolled hypertension, or uncontrolled diabetes within 6 months prior to Screening.

11. Significant organ dysfunction that is unstable or inadequately treated within 6 months prior to Screening.

12. History of cancer or lymphoproliferative disease, except for the following: adequately treated basal cell or squamous cell skin cancer without current evidence of disease.

13. Currently receiving any chronic systemic (oral or intravenous) anti-infective therapy for chronic infection (such as pneumocystis, cytomegalovirus, herpes zoster, or atypical mycobacteria).

14. Active tuberculosis (TB) (based on TB blood test or a TB skin test) or a history of inadequately treated TB.

15. Herpes zoster or cytomegalovirus (CMV) that resolved less than 2 months prior to Screening. Subjects with a history of frequent outbreaks of Herpes Simplex Virus (defined as 4 or more outbreaks a year).

16. Major surgery within 3 months prior to Screening visit or has a major surgery planned during the study.

17. Active systemic infection requiring parenteral antibiotic/antiviral therapy. All prior infections must have resolved following optimal therapy.

18. Prior organ allograft or allogeneic transplantation.

19. Positive based on serological screening for human immunodeficiency virus (HIV), hepatitis B or hepatitis C at screening.

20. Any ongoing toxicity from prior therapies that, in the judgment of the Investigator, may interfere with study treatment. All toxicities attributed to prior therapy must resolve to grade 1 or baseline before administration of the study treatment.

21. Psychiatric illness/social situations that would limit compliance with study requirements.

22. Other skin conditions that would interfere with study assessments of AA.

23. Other illness or a medical issue that in the opinion of the Investigator would exclude the subject from participating in this study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

HCW Biologics

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

James A. Haley Veterans' Hospital

Tampa, Florida, United States

Site Status: RECRUITING

The Ohio State University Wexner Medical Center

Columbus, Ohio, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Pallavi Chaturvedi, PhD.

Role: CONTACT

clinical@hcwbiologics.com

19548422024

Facility Contacts

Adam Zoble, MS

Role: primary

Adam.Zoble@va.gov

813-972-2000 ext. 106939

Alison Wandling, B.S. CCRC

Role: primary

Alison.Wandling@osumc.edu

614-685-0251

Other Identifiers

HCWALO101

Identifier Type: -

Identifier Source: org_study_id